Skin Cancer (Nonmelanoma)

BCC, SCC treatments take advantage of refinements in established techniques and new technology.

The anti–PD-L1, fully human monoclonal antibody cosibelimab will be examined in a cohort of patients with metastatic cutaneous squamous cell carcinoma (cSCC) as part of an ongoing phase 1 study.

Christopher Bunick, MD, PhD, associate professor of dermatology, Yale University and Dermatology Times® editorial advisory board member, weighs in on a recent report revealing certain batches of various sunscreen and after-sun care products were contaminated with benzene, a carcinogen.

David Light, founder and CEO of Valisure, the independent lab that discovered the presence of benzene in multiple brands and batches of sunscreen, sits down with Dermatology Times to discuss the reports' findings and the impact this news will have on the sun protection industry.

A recent test found various brands and batches of sunscreen and after-sun care products contained benzene, a potential carcinogen.

Content-aware image restoration (CARE) technology demonstrated improvement in examining cellular details of skin.

Research analyses found an increased risk of cSCC after AK diagnosis during long periods of follow up.

A study published in JAMA Dermatology investigated how consumers look at sunscreen active ingredients in response to an FDA proposed rule.

New data from a phase 3 study evaluating SGX301 for treatment of cutaneous T-cell lymphoma (CTCL) skin symptoms was recently presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX 2021).

In this video interview, Melissa Stenstrom, MD, discusses how physicians can promote the use of sun protection and regular skin cancer screenings to help prevent skin cancer among their patients.

A survey from the American Academy of Dermatology found that younger generations lack skin cancer knowledge.

Artificial intelligence diagnostics are less accurate on skin of color than light skin, even when trained on equal numbers of images.

In part 2 of this skin cancer report from the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX), an expert shares pearls on regular medication reviews.

More detailed tumor classifications, patient data advance surveillance strategies for the high-risk patient population.

Todd Schlesinger, MD, FAAD, outlines his research on newly FDA-approved topical tirbanibulin (Klisyri, Almirall) for treatment of actinic keratosis (AK), as well as compares it to another topical treatment for AK, 5-fluorouracil.

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

Biofrontera announces it is seeking FDA-approval for its new BF-RhodoLED XL lamp to be used in combination with topical aminolevulinic acid hydrochloride gel 10% for the treatment of actinic keratosis.

Cancer staging systems for squamous cell carcinoma have helped improve dermatologists’ ability to accurately stage the cancer, according to one expert.

Almirall announces the launch of tirbanibulin (Klisyri), a novel microtubule inhibitor for the topical treatment of actinic keratosis on the face or scalp.

Topical microtubule inhibitor, tirbanibulin (Klisyri, Almirall), demonstrates positive results for treating actinic keratosis (AK) of the face and scalp, according recently published data from two phase 3 studies.

The FDA has approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.

A recent study found states' Medicare per-beneficiary spending between actinic keratosis and skin cancer differs widely.

While Mohs micrographic surgery is well established as a safe and effective therapeutic modality in adult patients, it is not as commonly used in pediatric populations. There are unique challenges to performing Mohs surgery on pediatric patients, especially with patient cooperation. Multidisciplinary planning may be needed.

Investigators of a recent study found a 40-gene expression profile (40-GEP) test helps improve identification of high risk for metastatic disease in patients with cutaneous squamous cell carcinoma (cSCC).

Superficial radiation offers a newer, FDA-approved office-based option that is safe. Steven A. Davis, M.D., shares his experience using surface radiotherapy to treat his patients with non-melanoma skin cancer.

Promising outcomes are being reported from clinical trials investigating Nano-Pulse Stimulation technology to treat nodular basal cell carcinoma and cutaneous, non-genital warts.

Michelle Nguyen, M.D., MPH, sits down with Dermatology Times to discuss her recent presentation at the 2020 American Society for Dermatologic Surgery (ASDS) virtual meeting regarding the representation of women dermatologic surgeons in the U.S.

A recent study showed that curettage and cryotherapy, and electrodesiccation and curettage are two techniques that have comparable cure rates. The study’s findings highlight the efficacy and reliability of these treatment approaches for minimally invasive cutaneous carcinomas.

A recent study underscores the need for a consistent scale to grade risk levels of cutaneous squamous cell carcinoma (SCC), particularly poorly differentiated tumors, according to study authors who presented at the 2020 virtual American Society for Dermatologic Surgery (ASDS) meeting.

A recent survey shows that many consumers are confused about sunscreen labeling claims regarding sun protection factor (SPF), allergenicity and other features.